Ralf Morgenstern
Corporate Officer/Principal bij Karolinska Institutet
Actieve functies van Ralf Morgenstern
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | 06-05-2010 | - |
Loopbaan van Ralf Morgenstern
Eerdere bekende functies van Ralf Morgenstern
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Directeur/Bestuurslid | 26-10-2004 | - |
Oprichter | 26-10-2004 | - |
Statistieken
Internationaal
Zweden | 3 |
Operationeel
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Founder | 1 |
Sectoraal
Consumer Services | 2 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Health Technology |
- Beurs
- Insiders
- Ralf Morgenstern
- Ervaring